In vitro evaluation of a hybrid drug-delivery nanosystem for fibrosis prevention in cell therapy for Type 1 diabetes.
Nanomedicine (Lond)
; 18(1): 53-66, 2023 01.
Article
em En
| MEDLINE
| ID: mdl-36938861
This work describes a new drug-delivery system that can release an immunomodulatory drug in a controlled manner and prevent fibrosis, which is part of the immune response when a foreign body is implanted. This system can be particularly useful for insulin-secreting cell implants, used to replace multiple daily injections of insulin and improve the quality of life of people with Type 1 diabetes mellitus. By preventing the immune response that leads to fibrosis, the longevity of these cellular implants can be extended without the need for frequent replacement procedures. This innovative nanosystem can release the required amount of immunomodulatory drug, which could be stimulated with the use of special light, hence showing the ability for local and extended delivery. This type of system has the potential to reduce the side effects associated with oral daily administration of immunomodulatory agents in people with Type 1 diabetes mellitus.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Nanoestruturas
/
Diabetes Mellitus Tipo 1
/
Nanopartículas
Limite:
Humans
Idioma:
En
Revista:
Nanomedicine (Lond)
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Austrália